NCT05065411: Efficacy & Safety Evaluation of Enobosarm in Combo With Abemaciclib in Treatment of ER+HER2- Metastatic Breast Cancer

NCT05065411
Breast Cancer Type: HR+ & HER2-negative
Hormone Mutations: ER+, AR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Not yet recruiting
Phase 2
Drug Category: Serine-Threonine Kinase Inhibitor, Endocrine (Hormone Therapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years to 100 Years (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients who have not previously been treated & progressed on either 1) nonsteroidal aromatase inhibitor plus palbociclib OR 2) fulvestrant plus palbociclib for metastatic breast cancer; Patients with unstable symptomatic central nervous system metastases – see trial for details
https://ClinicalTrials.gov/show/NCT05065411

Comments are closed.

Up ↑